Literature DB >> 12088727

Synthesis and evaluation of 99mTc(CO)(3)-DTPA-folate as a folate-receptor-targeted radiopharmaceutical.

David P Trump1, Carla J Mathias, Zhenfan Yang, Philip S Low, Mary Marmion, Mark A Green.   

Abstract

A folate-receptor-targeted 99mTc-radiopharmaceutical, [99mTc]Tc(CO)(3)DTPA-folate, was prepared by heating [99mTc]Tc(CO)(3)(H(2)O)(3)(+) in an aqueous solution of the previously reported DTPA-folate conjugate. The radiotracer was HPLC purified (> 98% radiochemical purity) and evaluated in vitro and in vivo as an agent for targeting folate-receptor-positive cells. [99mTc]Tc(CO)(3)DTPA-folate experienced high, folate-receptor-specific uptake in human KB tumor cells. Intravenous administration of [99mTc]Tc(CO)(3)DTPA-folate to athymic mice bearing KB cell tumor xenografts resulted in 99mTc tumor uptake of 1.8 +/- 0.5 and 3.3 +/- 0.2%ID/g (n = 3) at 30 minutes and 4 hours post-injection, respectively. Tumor uptake was reduced when folic acid was co-administered with the intravenous [99mTc]Tc(CO)(3)DTPA-folate, consistent with radiopharmaceutical localization being mediated by the folate receptor.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12088727     DOI: 10.1016/s0969-8051(02)00310-4

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  7 in total

1.  In vitro and in vivo targeting of different folate receptor-positive cancer cell lines with a novel 99mTc-radiofolate tracer.

Authors:  Cristina Müller; P August Schubiger; Roger Schibli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-05-24       Impact factor: 9.236

2.  Preclinical evaluation of novel organometallic 99mTc-folate and 99mTc-pteroate radiotracers for folate receptor-positive tumour targeting.

Authors:  Cristina Müller; Alexander Hohn; P August Schubiger; Roger Schibli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-06-09       Impact factor: 9.236

3.  High sensitivity: high-resolution SPECT-CT/MR molecular imaging of angiogenesis in the Vx2 model.

Authors:  Michal Lijowski; Shelton Caruthers; Grace Hu; Huiying Zhang; Michael J Scott; Todd Williams; Todd Erpelding; Anne H Schmieder; Garry Kiefer; Gyongyi Gulyas; Phillip S Athey; Patrick J Gaffney; Samuel A Wickline; Gregory M Lanza
Journal:  Invest Radiol       Date:  2009-01       Impact factor: 6.016

4.  Differential expression of folate receptor 1 in medulloblastoma and the correlation with clinicopathological characters and target therapeutic potential.

Authors:  Hailong Liu; Qianwen Sun; Mingshan Zhang; Zhihua Zhang; Xinyi Fan; Hongyu Yuan; Cheng Li; Yuduo Guo; Weihai Ning; Youliang Sun; Yongmei Song; Chunjiang Yu
Journal:  Oncotarget       Date:  2017-04-04

5.  Folate receptor targeted imaging using poly (ethylene glycol)-folate: in vitro and in vivo studies.

Authors:  Se-Lim Kim; Hwan-Jeong Jeong; Eun-Mi Kim; Chang-Moon Lee; Tae-Hyoung Kwon; Myung-Hee Sohn
Journal:  J Korean Med Sci       Date:  2007-06       Impact factor: 2.153

6.  Biodistribution of (99m)tc labeled integrin antagonist.

Authors:  Beom-Su Jang; Seung-Hee Park; In Soo Shin; Jin-Soo Maeng; Chang H Paik
Journal:  Toxicol Res       Date:  2013-03

Review 7.  Role of Nanotechnology and Their Perspectives in the Treatment of Kidney Diseases.

Authors:  J P Jose Merlin; Xiaogang Li
Journal:  Front Genet       Date:  2022-01-05       Impact factor: 4.599

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.